PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Effects of arsenic trioxide on the expression of ezrin in hepatocellular carcinoma.

Abstract The aim of the study was to investigate the effects of arsenic trioxide (As2O3) treatment on the expression of ezrin and serum alpha-fetoprotein (AFP) levels in hepatocellular carcinoma (HCC).A total of 24 patients (20 males and 4 females) with resectable HCC were treated with venous injection of As2O3 for 14 days (10 mg/d) before surgery. The ezrin expression and serum AFP levels were assessed before and after treatment, respectively.The serum AFP levels were 325.5 ng/L before treatment and 278.6 ng/L after treatment, with statistical significant difference (Z = -2.360, P < .05). The expression of ezrin was negative, weak positive, and strong positive in 11, 7, and 6 cases, respectively, before As2O3 treatment, and 17, 5, 2 cases respectively after the treatment. The difference between the 2 groups was statistically significant (χ = 5.619, P < .05). Also, the results showed that there was a significant correlation between the high serum AFP level (AFP ≥ 500 ng/L) and high expression of ezrin (χ = 8.080, P < .05).As2O3 treatment can significantly downregulate the expression of ezrin in HCC.
PMID
Related Publications

Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells.

Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial.

microRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma.

The effect and mechanism of arsenic trioxide on hepatocellular carcinoma.

Multicenter phase II clinical trial of arsenic trioxide injection in the treatment of primary hepatocarcinoma.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28858082
OWN - NLM
STAT- MEDLINE
DA  - 20170831
DCOM- 20170911
LR  - 20170912
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 35
DP  - 2017 Sep
TI  - Effects of arsenic trioxide on the expression of ezrin in hepatocellular
      carcinoma.
PG  - e7602
LID - 10.1097/MD.0000000000007602 [doi]
AB  - The aim of the study was to investigate the effects of arsenic trioxide (As2O3)
      treatment on the expression of ezrin and serum alpha-fetoprotein (AFP) levels in 
      hepatocellular carcinoma (HCC).A total of 24 patients (20 males and 4 females)
      with resectable HCC were treated with venous injection of As2O3 for 14 days (10
      mg/d) before surgery. The ezrin expression and serum AFP levels were assessed
      before and after treatment, respectively.The serum AFP levels were 325.5 ng/L
      before treatment and 278.6 ng/L after treatment, with statistical significant
      difference (Z = -2.360, P &lt; .05). The expression of ezrin was negative, weak
      positive, and strong positive in 11, 7, and 6 cases, respectively, before As2O3
      treatment, and 17, 5, 2 cases respectively after the treatment. The difference
      between the 2 groups was statistically significant (chi = 5.619, P &lt; .05). Also, 
      the results showed that there was a significant correlation between the high
      serum AFP level (AFP &gt;/= 500 ng/L) and high expression of ezrin (chi = 8.080, P &lt;
      .05).As2O3 treatment can significantly downregulate the expression of ezrin in
      HCC.
FAU - Lu, Wei
AU  - Lu W
AD  - Department of Interventional Medicine, Navy General Hospital of PLA, Beijing,
      China.
FAU - Yang, Chao
AU  - Yang C
FAU - Du, Peng
AU  - Du P
FAU - Zhang, Jun-Li
AU  - Zhang JL
FAU - Zhang, Jia-Cheng
AU  - Zhang JC
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Arsenicals)
RN  - 0 (Cytoskeletal Proteins)
RN  - 0 (Oxides)
RN  - 0 (ezrin)
RN  - S7V92P67HO (arsenic trioxide)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/administration &amp; dosage/pharmacology/*therapeutic use
MH  - Arsenicals/administration &amp; dosage/pharmacology/*therapeutic use
MH  - Carcinoma, Hepatocellular/blood/*drug therapy/surgery
MH  - Cytoskeletal Proteins/*drug effects/metabolism
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Infusions, Intravenous
MH  - Liver Neoplasms/blood/*drug therapy/surgery
MH  - Male
MH  - Middle Aged
MH  - Oxides/administration &amp; dosage/pharmacology/*therapeutic use
PMC - PMC5585476
EDAT- 2017/09/01 06:00
MHDA- 2017/09/12 06:00
CRDT- 2017/09/01 06:00
AID - 10.1097/MD.0000000000007602 [doi]
AID - 00005792-201709010-00006 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Sep;96(35):e7602. doi: 10.1097/MD.0000000000007602.